Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19742
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEapen, Renu S-
dc.contributor.authorNzenza, Tatenda C-
dc.contributor.authorMurphy, Declan G-
dc.contributor.authorHofman, M S-
dc.contributor.authorCooperberg, M-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2018-10-29-
dc.date.accessioned2018-11-04T23:49:52Z-
dc.date.available2018-11-04T23:49:52Z-
dc.date.issued2019-07-
dc.identifier.citationWorld Journal of Urology 2019; 37(7): 1255-1261-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19742-
dc.description.abstractThe heterogeneity of prostate cancer has made imaging modalities of crucial importance in this disease. Accurate diagnosis and staging of the volume and extent of disease, especially in advanced and metastatic prostate cancer, can help to tailor the timing and modalities of treatment. While MRI has been effective in the detection of significant prostate cancer, its use in the identification and quantification of extraprostatic disease is limited. This gap is now being filled by PSMA PET. PSMA PET scans have now been shown to have a role in all stages in the prostate cancer journey. Emerging evidence has shown its promise in primary staging, restaging and theranostics. In this paper, we review the evidence for the use of PSMA PET in the various stages of prostate cancer, from initial diagnosis to advanced metastatic disease where other systemic treatments have failed.-
dc.language.isoeng-
dc.subjectLutetium-
dc.subjectPET-
dc.subjectPSMA-
dc.subjectProstate cancer-
dc.subjectStaging-
dc.subjectTheranostics-
dc.titlePSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.-
dc.typeJournal Article-
dc.identifier.journaltitleWorld Journal of Urology-
dc.identifier.affiliationDepartment of Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Urology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationYoung Urology Researchers Organisation (YURO), Melbourne, Australiaen
dc.identifier.affiliationDepartment of Urology, Helen Diller Comprehensive Cancer Centre, University of California, San Francisco, USAen
dc.identifier.affiliationDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1007/s00345-018-2524-z-
dc.identifier.orcid0000-0001-8553-5618en
dc.identifier.orcid0000-0002-1157-7003en
dc.identifier.pubmedid30374609-
dc.type.austinJournal Article-
local.name.researcherEapen, Renu S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.